What oral acyclovir dosing regimen is recommended for a pregnant woman with shingles, and how should the dose be adjusted in renal impairment?

Oral Acyclovir for Shingles in Pregnancy

For a pregnant woman with shingles, treat with oral acyclovir 800 mg five times daily for 7-10 days, initiated within 72 hours of rash onset for maximum benefit. While the safety of acyclovir in pregnancy has not been definitively established, current registry data show no increased risk of major birth defects compared to the general population, and the benefits of treating maternal herpes zoster infection outweigh theoretical risks 1.

Dosing Regimen

Standard Dosing

• Acyclovir 800 mg orally five times daily for 7-10 days 2
• Treatment should begin within 72 hours of rash onset, ideally within 48 hours for optimal efficacy 3
• The 800 mg five times daily regimen is superior to lower doses (400 mg five times daily) and significantly shortens viral shedding, accelerates healing, reduces new lesion formation, and decreases acute pain 2

Pregnancy-Specific Considerations

The CDC guidelines explicitly state that oral acyclovir may be used for the first clinical episode of herpes during pregnancy 1. While these guidelines primarily address genital herpes, the same principles apply to herpes zoster (shingles), as both are caused by related herpesviruses. For life-threatening maternal HSV infections, IV acyclovir is indicated 1.

Pharmacokinetic studies demonstrate that acyclovir crosses the placenta, with cord blood levels ranging from 0.5 to 3 µmol/L—concentrations sufficient for antiviral activity 4. Peak and trough plasma concentrations in pregnant women are similar to non-pregnant adults, though slightly lower 4, 5. The drug is well-tolerated with no observed adverse effects in newborns exposed in utero 4, 5.

Renal Dose Adjustment

Acyclovir requires dose adjustment in renal impairment because it is primarily renally excreted and accumulation can cause neurotoxicity 3.

Adjustment Algorithm

The FDA label and clinical guidelines provide the following adjustments 3, 6:

• Creatinine clearance >25 mL/min: 800 mg orally every 4 hours (5 times daily) - standard dose
• Creatinine clearance 10-25 mL/min: 800 mg orally every 8 hours (3 times daily)
• Creatinine clearance <10 mL/min: 800 mg orally every 12 hours (twice daily)

End-Stage Renal Disease/Hemodialysis

For patients on hemodialysis 7, 8:

• Loading dose: 400 mg orally after dialysis
• Maintenance: 200 mg orally twice daily
• Post-dialysis supplementation: Additional 400 mg after each dialysis session

This modified regimen maintains therapeutic plasma levels (6-8 µmol/L needed for herpes zoster) while preventing neurotoxicity 8.

Critical Safety Considerations

Neurotoxicity Risk

Acyclovir neurotoxicity is a serious concern in renal impairment, typically developing within 24-48 hours of therapy initiation 9, 10. Symptoms include confusion, altered mental status, hallucinations, tremors, and potentially obtundation. Risk factors include:

• Renal impairment (most important)
• Elderly patients
• Dehydration
• Concomitant nephrotoxic drugs 3, 9

The metabolite CMMG (9-carboxymethoxymethylguanine) accumulates in renal failure and is highly associated with neurotoxicity when serum levels exceed 10 µmol/mL 11. Neurotoxicity is reversible upon drug discontinuation, with hemodialysis removing approximately 51% of acyclovir in 4-5 hours 8.

Preventive Measures

• Maintain adequate hydration throughout therapy 3
• Avoid concomitant nephrotoxic agents 3
• Monitor renal function, especially in elderly patients or those with baseline impairment 3
• If neurological symptoms develop, immediately discontinue acyclovir and consider forced diuresis or hemodialysis 9

Pregnancy Registry

Women receiving acyclovir during pregnancy should be reported to the pregnancy registry (historically maintained by the manufacturer in cooperation with CDC) 1. Current accumulated data provide reassurance regarding birth defect risk, though the sample size remains insufficient for definitive conclusions 1.

Clinical Pearls

• Timing is critical: Treatment initiated beyond 72 hours after rash onset has limited data supporting efficacy 3
• Immunocompromised patients may require higher doses (acyclovir 400 mg orally 3-5 times daily) or IV therapy (5 mg/kg every 8 hours) for severe cases 1
• The 800 mg five times daily regimen is specifically validated for herpes zoster and should not be reduced to lower doses used for genital herpes suppression 2
• Acyclovir may be administered with or without food 3